{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:31:36Z","timestamp":1794018696816,"version":"4.8.0"},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2022JDR0326"],"award-info":[{"award-number":["2022JDR0326"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["2023JDR0246"],"award-info":[{"award-number":["2023JDR0246"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>At present, there are some differences in the research results of nirmatrelvir\u2013ritonavir compared with other antiviral drugs for the treatment of COVID\u201019 patients. We aimed to evaluate the efficacy and safety of nirmatrelvir\u2013ritonavir compared with other antiviral drugs and the impact of different antiviral drugs on the short\u2010 and long\u2010term effects of COVID\u201019. PubMed, Embase, CENTRAL (Cochrane Central Register of Controlled Trials), Web of Science, Google Scholar, and MedRxiv were searched to identify relevant studies from inception to March 30, 2023. We conducted a meta\u2010analysis to estimate the effects of nirmatrelvir\u2013ritonavir compared with other antiviral drugs for the treatment of COVID\u201019 patients and safety outcomes. The RoB1 and ROBINS\u2010I were used to assess the bias risk of the included studies. Revman 5.4 software was used for meta\u2010analysis (PROSPERO Code No: CRD42023397816). Twelve studies were included, including 30\u2009588 COVID\u201019 patients, of whom 13\u2009402 received nirmatrelvir\u2013ritonavir. The meta\u2010analysis results showed that the nirmatrelvir\u2013ritonavir group had a lower proportion of patients than the control group in terms of long\u2010term mortality (odds ratio [OR]\u2009=\u20090.29, 95% confidence interval [CI]: 0.13\u20130.66), hospitalization (OR\u2009=\u20090.44, 95% CI: 0.37\u20130.53, short term; OR\u2009=\u20090.52, 95% CI: 0.36\u20130.77, long term), and disease progression (OR\u2009=\u20090.56, 95% CI: 0.38\u20130.83, short term; OR\u2009=\u20090.60, 95% CI: 0.48\u20130.74, long term), and nirmatrelvir ritonavir showed little difference in safety compared to the control group. Nirmatrelvir\u2013ritonavir can reduce the mortality and hospitalization of COVID\u201019 patients compared with other antiviral drugs. Further large\u2010scale studies remain to validate these findings.<\/jats:p>","DOI":"10.1002\/jmv.28732","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T10:59:02Z","timestamp":1681383542000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Nirmatrelvir\u2013ritonavir compared with other antiviral drugs for the treatment of COVID\u201019 patients: A systematic review and meta\u2010analysis"],"prefix":"10.1002","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5187-0386","authenticated-orcid":false,"given":"Fangyuan","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Pharmacy, West China Hospital Sichuan University Chengdu China"},{"name":"Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital Sichuan University Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0181-1564","authenticated-orcid":false,"given":"Zhaoyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West China Hospital Sichuan University Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyi","family":"Feng","sequence":"additional","affiliation":[{"name":"Sichuan Provincial Key Laboratory of Precision Medicine, West China Hospital, Precision Medicine Research Center Sichuan University Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41562-022-01450-3"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27940"},{"key":"e_1_2_9_4_1","unstructured":"WHO.Coronavirus Disease COVID\u201019. Accessed February 14 2023.https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00320-6"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048172"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00016-0"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13081585"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00630-8"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac443"},{"key":"e_1_2_9_12_1","unstructured":"US Food & Drug Administration.Coronavirus (COVID\u201019) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID\u201019 in Certain Adults. 2021.https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100694"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.09.027"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28441"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208822"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10101731"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.17140"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.12.016"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28186"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00006-1"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac346"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00729-2"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000003740"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00507-2"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01586-0"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac687"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00127-8"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00126-6"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02051-3"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.18931"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106545"},{"key":"e_1_2_9_35_1","unstructured":"The COVID\u201019 Treatment Guidelines Panel (the Panel). Nirmatrelvir\u2010ritonavir. Accessed January 12 2023.https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/ritonavir-boosted-nirmatrelvir--paxlovid"},{"key":"e_1_2_9_36_1","unstructured":"National Health Commission of the People's Republic of China. Scheme for diagnosis and treatment of SARS\u2010CoV\u20102 (The 9th Trial Edition). Accessed February 16 2023.http:\/\/www.gov.cn\/zhengce\/zhengceku\/2022-03\/15\/content_5679257.htm"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-021-00202-8"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-022-00388-7"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02657-X"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.28732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T07:59:33Z","timestamp":1692259173000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.28732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1002\/jmv.28732"],"URL":"https:\/\/doi.org\/10.1002\/jmv.28732","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2023-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e28732"}}